# OnCo record ibi363 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ibi363/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ibi363" ;
  schema:name "IBI363"@en ;
  schema:description "IBI363 is an experimental fusion protein from Innovent Biologics (Suzhou) in phase 2 trials for melanoma, non-small-cell lung cancer and colorectal cancer, aimed at PD-1."@en ;
  schema:url <https://onco.cc/drugs/ibi363/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=IBI363> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "fusion protein" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/rcc/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/innovent/> ;
  onco:trials <https://onco.cc/trials/nct07722494/>, <https://onco.cc/trials/nct06797297/>, <https://onco.cc/trials/nct06081920/>, <https://onco.cc/trials/nct06281678/>, <https://onco.cc/trials/nct07122687/> .